FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma
- FDA approves treatment for two rare types of non-Hodgkin lymphoma. U.S. Food & Drug Administration. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM616176.htm?utm_campaign=08082018_PR_FDA%20approves%20new%20drug%20for%20two%20rare%20types%20of%20non-Hodgkin%20lymphoma&utm_medium=email&utm_source=Eloqua. Accessed online August 9, 2018.
- Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome. Press Release PR Newswire August 8, 2018. Available at https://markets.businessinsider.com/news/stocks/kyowa-kirin-announces-fda-approval-of-poteligeo-mogamulizumab-kpkc-for-the-treatment-of-mycosis-fungoides-and-s%C3%A9zary-syndrome-1027443628. Accessed online August 9, 2018.
- Poteligeo prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761051s000lbl.pdf. Accessed online August 9, 2018.